Cargando…

Assessment of increasing intravenous adenosine dose in fractional flow reserve

BACKGROUND: Effects of increased adenosine dose in the assessment of fractional flow reserve (FFR) were studied in relation to FFR results, hemodynamic effects and patient discomfort. FFR require maximal hyperemia mediated by adenosine. Standard dose is 140 μg/kg/min administrated intravenously. Hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Sparv, David, Götberg, Matthias, Harnek, Jan, Persson, Tobias, Madsen Hardig, Bjarne, Erlinge, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310024/
https://www.ncbi.nlm.nih.gov/pubmed/28196527
http://dx.doi.org/10.1186/s12872-016-0463-4
_version_ 1782507807137857536
author Sparv, David
Götberg, Matthias
Harnek, Jan
Persson, Tobias
Madsen Hardig, Bjarne
Erlinge, David
author_facet Sparv, David
Götberg, Matthias
Harnek, Jan
Persson, Tobias
Madsen Hardig, Bjarne
Erlinge, David
author_sort Sparv, David
collection PubMed
description BACKGROUND: Effects of increased adenosine dose in the assessment of fractional flow reserve (FFR) were studied in relation to FFR results, hemodynamic effects and patient discomfort. FFR require maximal hyperemia mediated by adenosine. Standard dose is 140 μg/kg/min administrated intravenously. Higher doses are commonly used in clinical practice, but an extensive comparison between standard intravenous dose and a high dose (220 μg/kg/min) has previously not been performed. METHODS: Seventy-five patients undergoing FFR received standard dose adenosine, followed by high dose adenosine. FFR, mean arterial pressure (MAP) and heart rate (HR) were analyzed. Patient discomfort measured by Visual Analogue Scale (VAS) was assessed. RESULTS: No significant difference was found between the doses in FFR value (0.85 [0.79–0.90] vs 0.85 [0.79–0.89], p = 0.24). The two doses correlated well irrespective of lesion severity (r = 0.86, slope = 0.89, p = <0.001). There were no differences in MAP or HR. Patient discomfort was more pronounced using high dose adenosine (8.0 [5.0–9.0]) versus standard dose (5.0 [2.0–7.0]), p = <0.001. CONCLUSIONS: Increased dose adenosine does not improve hyperemia and is associated with increased patient discomfort. Our findings do not support the use of high dose adenosine. TRIAL REGISTRATION: Retrospective Trial registration: Current Controlled Trials ISRCTN14618196. Registered 15 December 2016.
format Online
Article
Text
id pubmed-5310024
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53100242017-03-13 Assessment of increasing intravenous adenosine dose in fractional flow reserve Sparv, David Götberg, Matthias Harnek, Jan Persson, Tobias Madsen Hardig, Bjarne Erlinge, David BMC Cardiovasc Disord Research Article BACKGROUND: Effects of increased adenosine dose in the assessment of fractional flow reserve (FFR) were studied in relation to FFR results, hemodynamic effects and patient discomfort. FFR require maximal hyperemia mediated by adenosine. Standard dose is 140 μg/kg/min administrated intravenously. Higher doses are commonly used in clinical practice, but an extensive comparison between standard intravenous dose and a high dose (220 μg/kg/min) has previously not been performed. METHODS: Seventy-five patients undergoing FFR received standard dose adenosine, followed by high dose adenosine. FFR, mean arterial pressure (MAP) and heart rate (HR) were analyzed. Patient discomfort measured by Visual Analogue Scale (VAS) was assessed. RESULTS: No significant difference was found between the doses in FFR value (0.85 [0.79–0.90] vs 0.85 [0.79–0.89], p = 0.24). The two doses correlated well irrespective of lesion severity (r = 0.86, slope = 0.89, p = <0.001). There were no differences in MAP or HR. Patient discomfort was more pronounced using high dose adenosine (8.0 [5.0–9.0]) versus standard dose (5.0 [2.0–7.0]), p = <0.001. CONCLUSIONS: Increased dose adenosine does not improve hyperemia and is associated with increased patient discomfort. Our findings do not support the use of high dose adenosine. TRIAL REGISTRATION: Retrospective Trial registration: Current Controlled Trials ISRCTN14618196. Registered 15 December 2016. BioMed Central 2017-02-14 /pmc/articles/PMC5310024/ /pubmed/28196527 http://dx.doi.org/10.1186/s12872-016-0463-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Sparv, David
Götberg, Matthias
Harnek, Jan
Persson, Tobias
Madsen Hardig, Bjarne
Erlinge, David
Assessment of increasing intravenous adenosine dose in fractional flow reserve
title Assessment of increasing intravenous adenosine dose in fractional flow reserve
title_full Assessment of increasing intravenous adenosine dose in fractional flow reserve
title_fullStr Assessment of increasing intravenous adenosine dose in fractional flow reserve
title_full_unstemmed Assessment of increasing intravenous adenosine dose in fractional flow reserve
title_short Assessment of increasing intravenous adenosine dose in fractional flow reserve
title_sort assessment of increasing intravenous adenosine dose in fractional flow reserve
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310024/
https://www.ncbi.nlm.nih.gov/pubmed/28196527
http://dx.doi.org/10.1186/s12872-016-0463-4
work_keys_str_mv AT sparvdavid assessmentofincreasingintravenousadenosinedoseinfractionalflowreserve
AT gotbergmatthias assessmentofincreasingintravenousadenosinedoseinfractionalflowreserve
AT harnekjan assessmentofincreasingintravenousadenosinedoseinfractionalflowreserve
AT perssontobias assessmentofincreasingintravenousadenosinedoseinfractionalflowreserve
AT madsenhardigbjarne assessmentofincreasingintravenousadenosinedoseinfractionalflowreserve
AT erlingedavid assessmentofincreasingintravenousadenosinedoseinfractionalflowreserve